Page last updated: 2024-10-30

losartan and Nasopharyngeal Carcinoma

losartan has been researched along with Nasopharyngeal Carcinoma in 1 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Nasopharyngeal Carcinoma: A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Lin, YT1
Wang, HC1
Tsai, MH1
Su, YY1
Yang, MY1
Chien, CY1

Other Studies

1 other study available for losartan and Nasopharyngeal Carcinoma

ArticleYear
Angiotensin II receptor blockers valsartan and losartan improve survival rate clinically and suppress tumor growth via apoptosis related to PI3K/AKT signaling in nasopharyngeal carcinoma.
    Cancer, 2021, 05-15, Volume: 127, Issue:10

    Topics: Angiotensin Receptor Antagonists; Apoptosis; Humans; Losartan; Nasopharyngeal Carcinoma; Nasopharyng

2021